CATEGORIE

Esaote Introduces the MyLab™9 Ultrasound Platform

domenica 15 ottobre 2017

2' di lettura

- ESAOTE introduces the MyLab™9, the flagship platform in its Ultrasound portfolio which defines a new standard in image CLARITY, smart WORKFLOW, solid PERFORMANCE. The MyLab™9 eXP will be launched at JFR 2017 in Paris, October 13th-16th, Palais des Congrès, BOOTH 1N01 - Level 1 - Hall Neuilly.      (Logo: http://mma.prnewswire.com/media/557501/ESAOTE_Logo.jpg )      (Photo: http://mma.prnewswire.com/media/557506/Esaote_MyLab.jpg ) "The MyLab™9 platform represents a new chapter for Esaote," said Luca Bombino, High-End Ultrasound Product Marketing Manager. "We invested in technologies that have a real clinical impact, improving image acquisition, diagnostic confidence and patient throughput. Our multi-modality approach allows quick access to other imaging modalities and PACS systems, for immediate clinical follow up and fusion imaging. At Esaote, we believe this is an important step for a more informed and efficient healthcare system." The MyLab™9 eXP takes advantage of cutting-edge manufacturing to offer an ultra-ergonomic experience, such as the easyMode unique touch-tool for image optimization. "In everyday clinical practice, it's crucial to be precise, and confident at the same time. The easyMode technology allows the operators to conduct the examination with a focus on the patient, without distractions or complex technical routines of the system," said Carlo Biagini, MD, Radiologist, Florence, Italy. Developed to provide ultra-quality ultrasound technology to hospitals, clinics and private practices, the MyLab™9 eXP offers smart upgradability, remote serviceability, long-term maintenance options and transducer compatibility. For more information visit www.esaote.com Massimo Rosa, Esaote Chief Global Marketing Officer said "Today economic constraints, and the increase in average life expectancy, are opposing forces. The MyLab™9 eXP provides advanced diagnostic capabilities and clinical efficacy to respond effectively to the most demanding healthcare needs expanding the access to innovative technologies for more customers." About Esaote: With a consolidated turnover of EUR 270 million in 2016, the Esaote Group is a leader in the biomedical equipment sector, in particular the areas of ultrasound, dedicated MRI and software for managing the diagnostic process. The Group currently employs 1,200 people. With its own production and research units in Italy and the Netherlands, Esaote is recognised as one of the top 10 diagnostic imaging companies in the world. Information on Esaote and its products is available at www.esaote.com © Copyright Esaote 2017 Technology and features are system/configuration dependent. Specifications are subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative. Communications & External Relations: Mariangela Dellepiane, Tel.: +39-010-6547249 , e-mail: mariangela.dellepiane@esaote.com

tag

Ti potrebbero interessare

Philip Morris International annuncia la ri-autorizzazione di IQOS da parte della FDA statunitense come Prodotto del Tabacco a Rischio Modificato

La Food and Drug Administration (FDA) degli Stati Uniti ha annunciato di aver autorizzato il rinnovo degli ordini di com...

Teatro San Carlo, l'incontro con il Maestro Gustavo Dudamel: "Momento di crescita e condivisione"

Trentacinque giovani musicisti dell’Orchestra Sanitansamble di Napoli hanno incontrato il Maestro Gustavo Dudamel ...
Redazione

Touchpoint Awards Identity: Fkdesign conquista il Grand Award 2026 con il rebranding della Cooperativa L’Incontro

Nella cornice milanese di Fabbrica di Lampadine si è svolta la cerimonia di premiazione, condotta da Luca Viscard...

MIM, presentate le buone pratiche delle scuole contro il bullismo. Valditara: “Studenti e docenti hanno già in sé la forza e le capacità di sconfiggere la violenza”

Giovedì 16 aprile il Ministro dell’Istruzione e del Merito Giuseppe Valditara è intervenuto all&rsqu...